21st Dec 2020 09:23
(Alliance News) - AstraZeneca PLC on Monday said Tagrisso has been approved in the US for the treatment of patients with early-stage lung cancer.
The FTSE 100-listed Anglo-Swedish drug manufacturer said the approval - granted under the US Food & Drug Administration's real-time oncology review pilot program - was based on results from the Adaura Phase III trial which showed Tagrisso reduced the risk of disease recurrence or death by 83% in patients with stage 2 and 3a early-stage lung cancer. Results also showed that in patients with stage 1b to Stage 3a of the disease, Tagrisso reduced the risk of disease recurrence or death by 80%.
Astra added that at two years, 89% of patients treated with Tagrisso remained alive and disease free compared with 52% on placebo after surgery.
The drug is currently under regulatory review in China and the EU.
Shares in AstraZeneca were trading 0.3% higher at 7,530.00 pence each on Monday morning in London
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca